Clin Adv Hem Onc
@clinadvances
Followers
1K
Following
5
Media
35
Statuses
1K
Clinical Advances in Hematology & Oncology is a monthly peer-reviewed medical journal.
New York City
Joined September 2011
“Sequencing Antibody-Drug Conjugates in Patients with Hormone Receptor–Positive, HER2 Negative Metastatic Breast Cancer” with Javier Cortés, MD, PhD @JavierCortesMD.
hematologyandoncology.net
Explore optimal sequencing of antibody-drug conjugates (ADCs) like T-DXd, SG, and Dato-DXd in HR+/HER2– metastatic breast cancer, emphasizing early intervention.
0
0
0
“Reducing Drug Toxicity and Costs Through Off-Label Dosing” with Mark J. Ratain, MD
hematologyandoncology.net
Explore off‑label dosing strategies to reduce drug toxicity and costs in oncology, including dose optimization, therapeutic drug monitoring, and patient-centered outcomes.
0
0
0
“Is Doublet Therapy Becoming a Standard of Care in Myelofibrosis?” with Raajit K. Rampal, MD, PhD @RaajitRampal @MSKCancerCenter.
hematologyandoncology.net
Explore the evolving role of doublet therapies in myelofibrosis, focusing on combinations like ruxolitinib with pelabresib and navitoclax, and their impact on treatment outcomes.
0
0
0
“Highlights in Upper Gastrointestinal Cancer From the 2025 American Society of Clinical Oncology Annual Meeting” #uppergastrointestinalcancer #gastrointestinalcancer @ASCO.
hematologyandoncology.net
Review key advances in upper gastrointestinal cancer, covering esophageal, gastric, and small intestine cancer treatment updates and emerging therapies.
0
0
0
RT @mtmdphd: Room for Improvement: Immunization for Pts w/ Monoclonal B-Cell Lymphocytosis or CLL [Jul 2014] Whitaker et al. @clinadvances….
hematologyandoncology.net
July 2014, Volume 12, Issue 7 Jennifer A. Whitaker, MD, MS, Tait D. Shanafelt, MD, Gregory A. Poland, MD, and Neil E. Kay, MD The authors […]
0
1
0
“The Addition of Darolutamide to Androgen Deprivation Therapy in Metastatic Hormone- Sensitive Prostate Cancer” with Fred Saad, MD #prostatecancer.
hematologyandoncology.net
Explore the ARANOTE trial results: Darolutamide combined with androgen deprivation therapy significantly reduced radiographic progression in metastatic hormone-sensitive prostate cancer.
0
0
0
“First-line Use of Antiangiogenic Agents in Unresectable Hepatocellular Carcinoma: A Double- Edged Sword?” by Aditya Mahadevan, MD and colleagues. @abijaoudehn @DrHarryDOesHep @uciphysicians @ucirvine.
hematologyandoncology.net
Explore the pros and cons of first-line antiangiogenic therapies in unresectable HCC, including VEGF inhibitors and immune checkpoint inhibitors.
0
0
1
“Revolutionizing Breast Cancer Treatment: The Promise of Antibody-Drug Conjugates” by Samer Alkassis, MD; John A. Glaspy, MD, MPH; and Aditya Bardia, MD, MPH @AlkassisSamer @dradityabardia @UCLA #BreastCancer.
hematologyandoncology.net
Explore the role of antibody-drug conjugates (ADCs) in breast cancer treatment, including FDA-approved agents like T-DM1, T-DXd, SG, and Dato-DXd.
0
0
0
“The Addition of Darolutamide to Androgen Deprivation Therapy in Metastatic Hormone- Sensitive Prostate Cancer” with Fred Saad, MD #prostatecancer.
hematologyandoncology.net
Explore the ARANOTE trial results: Darolutamide combined with androgen deprivation therapy significantly reduced radiographic progression in metastatic hormone-sensitive prostate cancer.
0
0
0
The latest issue of Clinical Advances in Hematology & Oncology is now available online #hematology #oncology #hemonc #cancer #LLM #breastcancer #prostatecancer.
0
0
0
“Non–Clear Cell Renal Cell Carcinoma: Unpacking a Messy Term” by Angelina Bania, MD; Giannicola Genovese, MD, PhD; and Pavlos Msaouel, MD, PhD @LabGenovese @PavlosMsaouel @MDAndersonNews #carcinoma.
hematologyandoncology.net
Abstract: Non–clear cell renal cell carcinoma (nccRCC) is a heterogeneous category comprising approximately 25% of epithelial renal tumors. Unlike their far more common clear cell counterpart, […]
0
2
5
“Update on LAG3 and Immunotherapy Combinations in Melanoma” with Hussein A. Tawbi, MD, PhD @HTawbi_MD @MDAndersonNews #melanoma.
hematologyandoncology.net
H&O How does the mechanism of action of LAG3-targeted therapies differ from that of other immune checkpoint inhibitors? HT LAG3-targeted therapy unlocks an entirely new pathway […]
0
0
1
“The Development of BTK Degraders for Patients With Relapsed CLL” with Alexey V. Danilov, MD, PhD @cityofhope #CLL.
hematologyandoncology.net
H&O What are Bruton tyrosine kinase (BTK) degraders, and how do they differ from BTK inhibitors? AD BTK degraders are from a new class of molecules, […]
0
0
0
“The Use of Biomarkers in Advanced, Locally Advanced, and Early-Stage Lung Cancer” with Narjust Florez, MD @NarjustFlorezMD @Harvardmed #lungcancer.
hematologyandoncology.net
H&O How has biomarker testing evolved differently for early-stage vs advanced lung cancer? NF We have good data regarding the use of biomarkers for neoadjuvant therapy […]
0
0
0
“Intrathecal Immunotherapy in Patients Who Have Melanoma With Leptomeningeal Disease” with Isabella C. Glitza Oliva, MD, PhD @MDAndersonNews #melanoma.
hematologyandoncology.net
H&O What is the rationale behind the use of immunotherapy for intrathecal treatment of leptomeningeal disease (LMD)? ICG When we talk about treatments before the new […]
0
0
0
“Letter From the Editor: What Would You Do?” by Daniel J. George, MD @Daniel_J_George.
hematologyandoncology.net
As oncologists, how many times have we had to answer the question, “What would you do?” There is always the temptation to answer it with a […]
0
0
0
“The Development of ATR Inhibitors” with Timothy A. Yap, MBBS, PhD @MDAndersonNews.
hematologyandoncology.net
Explore how ATR inhibitors target DNA damage response in cancer cells, offering new treatment avenues for tumors with ATM, BRCA1/2, and other mutations.
0
0
1
“Treatment Deintensification in Locally Advanced Rectal Cancer: When Less Is More” with Andrea Cercek, MD @AndreaCercek @MSKCancerCenter @CYOC_MSK #colorectalcancer.
hematologyandoncology.net
Explore strategies to reduce treatment intensity in locally advanced rectal cancer, focusing on organ preservation and patient quality of life.
0
0
0
“Radiation Therapy and MRI-Based Treatments in Non–Small Cell Lung Cancer” with Percy Lee, MD @PercyLeeMD @cityofhope @cityofhopeoc #lungcancer.
hematologyandoncology.net
Explore advancements in radiation therapy and MRI-guided treatments for non–small cell lung cancer, including SBRT, immunotherapy integration, and MRI's role.
0
0
0
“Development of Chimeric Antigen Receptor Natural Killer–Cell Therapy” with Katy Rezvani, MD, PhD @lab_rezvani @MDAndersonNews #LLM.
hematologyandoncology.net
Explore the advancements in CAR NK-cell therapy, highlighting its safety, efficacy, and potential as an off-the-shelf treatment for various cancers.
0
0
0